GSK heads to Cambridge with long-awaited positive vibes Pharmaceutical company’s move to new £400m research centre accompanied by encouraging news for shareholders The Guardian - UK · Jul 28
GSK to cut jobs amid £1.9bn cost-cutting plan and bid for faster drug development Pharmaceuticals company is investing £400m in UK life sciences and moving scientists to new Cambridge R&D site The Guardian - UK · Jul 28
GSK makes biggest ever acquisition with $10.6bn for US cancer drug firm Nuvalent’s late-stage lung cancer treatments zidesamtinib and neladalkib are expected to launch later this year The Guardian - UK · Jun 9
Shot in the arm for GSK and AstraZeneca from cancer drug sales The blue chip drug makers saw first quarter earnings beat market expectations. Evening Standard · Apr 29
GSK reports promising early results in ovarian and womb cancer drug trial Mo-Rez reduced or eliminated tumours in over 60% of patients and is expected to be a blockbuster drug The Guardian - UK · Apr 12
Emma Walmsley’s pay rose almost 50% to £15.6m in final year as GSK boss Bulk of 2025 renumeration came from share bonuses as drug company’s now former CEO benefitted from stock rise The Guardian - UK · Mar 5
GSK, take two: the bullish tone at the top is finally more convincing New boss Luke Miels knows perils of overpromising but there is growing sense pharma firm is closer to filling potential The Guardian - UK · Feb 4
GSK posts higher profits but indicates sales growth to slow in 2026 It came amid the first set of results by new chief executive Luke Miels, who took over from Emma Walmsley at the turn of the year. Evening Standard · Feb 4
FTSE 100 Live 04 February: GSK milestone as index soars to new record, AI data jitters continue GSK results today helped shares surge above 2000p for the first time in over two decades as the FTSE 100 index set a new intraday record. Evening Standard · Feb 4
GSK cutting jobs in UK and US as part of ongoing R&D changes It is understood around 50 UK jobs so far are being cut in the group’s main UK R&D hub in Stevenage, Hertfordshire. Evening Standard · Feb 2
Drugs giant to axe up to 350 R&D jobs across the US and UK About 50 jobs will be impacted in the group’s main UK R&D hub in Stevenage, Hertfordshire The Independent UK · Feb 2
Emma Walmsley To Step Down As GSK CEO After Nine Years, Luke Miels To Lead Starting January 2026 GSK plc (NYSE: GSK) appointed Luke Miels as the CEO Designate of GSK. He will assume full responsibility as CEO and join the Board on January 1, 2026. Benzinga · Sep 29, 2025
Emma Walmsley steps down as CEO of GSK as pharmaceutical industry faces upheaval The drug and vaccine maker is a £60bn firm – one of the biggest in the UK The Independent UK · Sep 29, 2025
GSK Switches CEO As Trump Tariffs Test Pharma British pharmaceutical giant GSK on Monday said longtime chief executive Emma Walmsley will be replaced by its chief commercial officer in January, as the company navigates US tariffs on the sector. International Business Times · Sep 29, 2025
Evening Standard · Sep 29, 2025 GSK’s boss Emma Walmsley to step down after eight-year tenure Dame Emma was the first woman to run a major pharmaceutical company when she became chief executive in 2017.
The Guardian - UK · Sep 29, 2025 GSK’s Emma Walmsley to step down as chief executive after eight years Chief commercial officer Luke Miels to take over as CEO at Britain’s second-biggest drugmaker